Overview

Adrafinil is a synthetic benzhydryl sulfinyl compound first developed in the late 1970s by the French pharmaceutical company Laboratoire Lafon. It functions as a prodrug of modafinil, being converted to its active metabolite primarily through hepatic amidase-mediated hydrolysis. Adrafinil was marketed in France under the brand name Olmifon for the treatment of narcolepsy and age-related drowsiness until its discontinuation in 2011, following the wider availability of modafinil itself.

The pharmacological profile of adrafinil closely mirrors that of modafinil, promoting wakefulness through mechanisms that likely involve adrenergic, dopaminergic, and histaminergic signaling, though the precise mechanism remains incompletely understood. Unlike amphetamines, adrafinil does not appear to produce significant euphoria, rebound hypersomnolence, or marked sympathomimetic effects. Its onset of action is slower than modafinil (typically 60-90 minutes) due to the additional metabolic conversion step required.

Because adrafinil undergoes hepatic metabolism to produce modafinil, chronic use raises concerns about liver enzyme elevation and hepatotoxicity. Liver function monitoring has been recommended for long-term users. Adrafinil is not a scheduled substance in most jurisdictions, unlike modafinil, which has contributed to its popularity in nootropic communities. However, it is banned by the World Anti-Doping Agency as a non-specified stimulant. Common side effects include headache, nausea, and insomnia.

Mechanism of Action

Prodrug Metabolism

Adrafinil is a prodrug that undergoes hepatic biotransformation to its active metabolite modafinil via hydrolytic cleavage of the diphenylmethyl sulfinyl hydroxamic acid moiety. This conversion is mediated by hepatic microsomal enzymes and esterases. A secondary metabolite, modafinilic acid (inactive), is also produced (PMID: 10498882).

Hypocretin/Orexin System

Modafinil, the active metabolite, activates hypothalamic orexin (hypocretin) neurons in the lateral hypothalamus. Orexin-A and orexin-B then activate OX1R and OX2R receptors on downstream wake-promoting nuclei including the tuberomammillary nucleus (histaminergic), locus coeruleus (noradrenergic), and dorsal raphe (serotonergic), stabilizing the wake state.

Dopamine Transporter Inhibition

Modafinil binds to the dopamine transporter (DAT) at the presynaptic terminal, inhibiting dopamine reuptake and increasing extracellular dopamine in the prefrontal cortex, nucleus accumbens, and striatum. This mechanism was confirmed by DAT-knockout studies showing abolished wake-promoting effects (PMID: 19037199).

Glutamate/GABA Balance

The compound enhances glutamatergic transmission while reducing GABAergic tone in cortical and subcortical regions. It increases extracellular glutamate in the medial preoptic area and posterior hypothalamus, while decreasing GABA in the cortex, medial preoptic area, and posterior hypothalamus, shifting the excitatory/inhibitory balance toward wakefulness.

Histaminergic Contribution

Adrafinil/modafinil increases histamine release from tuberomammillary nucleus neurons, contributing to cortical arousal through H1 receptor activation, though this appears secondary to orexin-mediated activation rather than direct histaminergic action.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Adrafinil

Common Side Effects

• CNS effects: Headache, dizziness, insomnia (especially with late-day dosing), anxiety, irritability
• GI effects: Nausea, stomach pain, diarrhea
• Dermatologic: Skin irritation, rash (uncommon)
• Other: Dry mouth, elevated blood pressure

Serious Adverse Effects

• Hepatotoxicity: Adrafinil requires hepatic conversion to modafinil (its active metabolite); this conversion produces modafinilic acid, which may cause liver enzyme elevation with chronic use — this was the primary safety concern leading to its limited adoption
• Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN): Rare but potentially fatal; same class effect as modafinil — discontinue immediately at first sign of rash
• Psychiatric effects: Rare reports of psychosis, mania, or suicidal ideation (class effect of eugeroics)
• Orofacial dyskinesia: Reported with chronic use in early French clinical data

Contraindications

• Known hypersensitivity to adrafinil or modafinil
• Severe hepatic impairment (hepatotoxicity risk)
• History of Stevens-Johnson syndrome or drug-induced rash with modafinil/armodafinil
• Unstable angina or recent myocardial infarction
• History of psychosis or severe anxiety disorders

Drug Interactions

• CYP3A4 substrates: Modafinil (active metabolite) induces CYP3A4, potentially reducing efficacy of: hormonal contraceptives, cyclosporine, midazolam, triazolam
• CYP2C19 substrates: Modafinil inhibits CYP2C19; may increase levels of: omeprazole, phenytoin, diazepam, propranolol
• Warfarin: Monitor INR — modafinil may affect warfarin metabolism
• Stimulants/caffeine: Additive CNS stimulation; increased cardiovascular risk
• MAOIs: Potential for hypertensive crisis; avoid combination

Special Populations

• Pregnancy/Lactation: Contraindicated — modafinil (active metabolite) is associated with congenital malformations (FDA pregnancy registry data)
• Pediatric: Not recommended; modafinil was denied pediatric approval by FDA due to Stevens-Johnson syndrome risk
• Elderly: Start with reduced doses; increased hepatic and cardiovascular sensitivity
• Renal impairment: Active metabolite is renally excreted; dose adjustment may be needed
• Hepatic impairment: Contraindicated in severe impairment; use with extreme caution in mild-moderate

Monitoring Recommendations

• Liver function tests (LFTs): Baseline and every 3 months with chronic use — this is critical and non-negotiable
• Blood pressure and heart rate monitoring
• Dermatologic assessment — discontinue immediately with any rash
• Psychiatric symptom monitoring
• CBC periodically (rare reports of blood dyscrasias with modafinil class)

Regulatory Note: Adrafinil was a prescription drug in France (Olmifon, discontinued 2011). It is unscheduled in the US but not FDA-approved. It is banned by WADA as a non-specified stimulant. Modafinil (Provigil), the active metabolite, is Schedule IV in the US and generally preferred due to the hepatotoxicity concern with adrafinil.

Pharmacokinetic Profile